Lmr Partners 13F: Cuts ABVX Stake by $2.4M

Lmr Partners Trims Holdings in ABIVAX Société Anonyme

Lmr Partners pared back its investment in ABIVAX Société Anonyme ABVX during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The fund reduced its position by 18,000 shares, bringing its total down to 76,552 shares. That change represented a 19.0% decrease from the previous quarter. The remaining stake carried a reported value of about $10.2 million at the time of the filing.

ABIVAX Shares Trade Near $132.83

The shares traded around $132.83, reflecting a spot price that sits comfortably above the 50-day moving average of $108.41 and the 200-day moving average of $116.29. The clinical-stage biotechnology firm carries a market value of roughly $8.06 billion. This pricing follows a volatile trading stretch that saw shares test a 52-week low of $69.81 before climbing as high as $148.83.

Wall Street Research Updates and Targets

Research firms have kept up active coverage on the developer of chronic inflammatory disease treatments. On July 1, 2026, Citizens reiterated its market outperform rating with a price target of $187.00. A few days later on July 2, 2026, Truist Securities maintained its buy rating and lifted its target from $135.00 to $155.00. Piper Sandler followed on July 9, 2026, maintaining an overweight rating while pushing its target up from $165.00 to $175.00. Later in the summer, BTIG reaffirmed a buy rating and a $175.00 target on September 5, 2026. Goldman Sachs initiated coverage on September 10, 2026, assigning a buy rating and a $155.00 target. Later in the month on September 22, 2026, Truist Securities maintained its buy rating while adjusting its target from $155.00 down to $151.00, Wedbush maintained a neutral rating and lowered its target from $140.00 to $118.00, and Barclays maintained an overweight rating at a $148.00 target.

Developing Immune-System Therapies in Paris

Headquartered in Paris, France, ABIVAX Société Anonyme focuses on building treatments that help stabilize the body's immune response for patients suffering from chronic inflammatory diseases. The firm centers its clinical pipeline on its lead candidate, obefazimod, which has advanced through late-stage testing for ulcerative colitis alongside mid-stage evaluations for Crohn's disease. The company employs a small team of 98 people to advance these programs.

Filing Details and What Comes Next

Institutional investment managers file 13F reports with the SEC after each quarter ends to disclose their stock ownership. These public disclosures offer a snapshot of institutional sentiment, though they look backward and may not reflect current holdings given active trading in the weeks since the filing date. Observers will watch for the company's next earnings report on March 22, 2027, for further updates on its drug pipeline and financial standing.